tdenv-f17
Vaccineexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2007 (NCT00370682)
Timeline
Indications
Studied for
Mechanism of action
- Dengue virusImmunity, active
Dengue virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- t-den f17
- t-den-f17
- tdenv-f17
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03110952 | Phase 1 | Jan 1, 2016 | GlaxoSmithKline, State University of New York, Syracuse, United States Army |
| NCT00468858 | Phase 2 | Jul 1, 2007 | Caparra Internal Medicine Research Center, GlaxoSmithKline, Ponce School of Medicine, San Juan Batista Medical School, United States Army |
| NCT00370682 | Phase 2 | Apr 1, 2007 | GlaxoSmithKline, United States Army |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 0 | 2 | 2007 |
| United States Army | Government | 3 | 3 | 2 | 2007 |
| Caparra Internal Medicine Research Center | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Ponce School of Medicine | Academic/Hospital | 1 | 0 | 1 | 2007 |
| San Juan Batista Medical School | Academic/Hospital | 1 | 0 | 1 | 2007 |
| State University of New York, Syracuse | Academic/Hospital | 1 | 0 | 1 | 2016 |
6 organizations
Page 1 / 1